Recent Updates on Imaging and Staging of Gynecologic Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 21 May 2025 | Viewed by 861

Special Issue Editors


E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Barnes Jewish Hospital, Washington University, St. Louis, MO 63110, USA
Interests: gynecologic oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA
Interests: gynecologic oncology

Special Issue Information

Dear Colleagues,

Endometrial cancer is one of the few forms of cancer that is increasing in incidence and mortality. This year, it is estimated that the mortality from endometrial cancer will exceed that from ovarian cancer. In order to treat this disease more effectively, we must have better imaging and a better understanding of its prognostic features. These features include molecular features that are responsible for the prognosis and, hence, spread of the disease. 

The management of endometrial cancer has evolved dramatically as we understand its spread better. This includes anatomic staging and molecular staging with associated imaging. New technologies and molecular features are evolving continuously.

We encourage you to submit to this Special Issue on these specific topics of imaging and features, both molecular and anatomic, that could lead to a better understanding of endometrial cancer.

Prof. Dr. David Mutch
Prof. Dr. Alexander B. Olawaiye
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • imaging
  • surgical staging
  • molecular prognostic features
  • mortality
  • prognosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2166 KiB  
Article
Prognostic Value of Pretreatment 18F-FDG-PET/CT Metabolic Parameters in Advanced High-Grade Serous Ovarian Cancer
by Daniela Travaglio Morales, Mónica Coronado Poggio, Carlos Huerga Cabrerizo, Itsaso Losantos García, Cristina Escabias del Pozo, Carmen Lancha Hernández, Sonia Rodado Marina and Luis Domínguez Gadea
Cancers 2025, 17(4), 698; https://doi.org/10.3390/cancers17040698 - 19 Feb 2025
Viewed by 580
Abstract
Aim: To assess the prognostic value of pretreatment 18F-FDG-PET/CT quantitative metabolic parameters in patients with advanced high-grade serous ovarian cancer (HGSOC). Methods: A review of 47 patients diagnosed with advanced HGSOC between 2012 and 2020 in our center was performed, evaluating pretreatment [...] Read more.
Aim: To assess the prognostic value of pretreatment 18F-FDG-PET/CT quantitative metabolic parameters in patients with advanced high-grade serous ovarian cancer (HGSOC). Methods: A review of 47 patients diagnosed with advanced HGSOC between 2012 and 2020 in our center was performed, evaluating pretreatment 18F-FDG-PET/CT metabolic parameters: maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG) and metabolic tumoral volume (MTV). Two experienced nuclear medicine physicians evaluated the images, thereby obtaining quantitative parameters semiautomatically classifying the volume of interest (VOI) as the target (t): VOI with the highest SUVmax normalized by lean body mass (SUVmax(lbm)), non target (nt) and total (sum of target and non-target VOIs). The disease-free survival (DFS) and overall survival (OS) were calculated. Optimal cutoff values with ROC curves/median values were used. The Correlation between metabolic parameters and DFS/OS was determined using univariate and survival-curves analysis. Results: The median DFS was 18 months (2.5–55) and the OS 33.6 months (2.5–92). The MTVtotal, MTV(t), TLGtotal and TLG(t) were significantly associated with DFS (p = 0.005, 0.01, 0.04 and 0.04, respectively). The patients with MTVtotal > 427.8 cm3 and MTVtarget > 434 cm3 had shorter DFS than the patients with lower values (18.8 versus 31 months and 15.6 versus 30, p = 0.02 and 0.01, respectively). The patients with higher TLGtotal and TLG(t) values tended to have worse DFS (p = 0.26 and 0.31, respectively). In a multivariate analysis, the MTVtotal was statistically significantly associated with DFS (p = 0.003). No correlation was found with OS. Conclusions: Pretreatment MTVtotal and MTV(t) appear to be predictive of relapse in patients with advanced HGSOC. Full article
(This article belongs to the Special Issue Recent Updates on Imaging and Staging of Gynecologic Cancers)
Show Figures

Graphical abstract

Back to TopTop